Samuel L Aitken

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2023 · 631 citations · Full text

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2022 · 458 citations · Full text

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2020 · 405 citations

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and<i>Pseudomonas aeruginosa</i>with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo et al. · Clinical Infectious Diseases · 2021 · 376 citations · Full text

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

José M. Munita, Samuel L Aitken, William R. Miller et al. · Clinical Infectious Diseases · 2017 · 134 citations · Full text

Multicenter Evaluation, Antimicrobial Chemotherapy, Drug Resistance +16